참고문헌
- British Thoracic Association. A controlled trial of six months chemotherapy in pulmonary tuberculosis: first report: results during chemotherapy. Br J Dis Chest 1981;75:141-53 https://doi.org/10.1016/0007-0971(81)90046-2
- Kim SJ, Bai GH, Hong YP. Drug resistance of Mycobacterium tuberculosis in Korea. Int J Tuberc Lung Dis 1997;1: 302-8
- World Health Organization. Guidelines for the programmatic management of drug-resistant tuberculosis. WHO/HTM/TB/ 2006.361. Geneva, Switzerland: WHO; 2006
- Steiner M, Cosio A. Primary tuberculosis in children : I. Incidence of primary drug resistant disease in 332 children observed between the years 1961 and 1964 at the Kings Country Medical Center of Brooklyn. N Engl J Med 1966; 274:755-9 https://doi.org/10.1056/NEJM196604072741401
- Jang SH, Cha YH, Ahn YM, Kim SJ. Drug-resistant tuberculosis in children. J Korean Pediatr Soc 1997;40:818-24
- Ganetti G, Fox W, Khmenko A, Mahler HT, Menon NK, Mitchison DA, Rist N, Smelev NA. Advances in techniques of testing mycobacterial drug sensitivity, and the use of sensitivity tests in tuberculosis control programmes. Bull Wld Hlth Org 1969;41:21-43
- Wane LG. Simple pyrazinamidase and urease tests for routine identification of mycobacteria. Am Rev Respir Dis 1974; 109:147-51
- Centers for Disease Control and Prevention. Revised definition of extensively drug-resistant tuberculosis. MMWR 2006;55:1176
- World Health Organization. Global tuberculosis control: suveillance, planning, financing. WHO/HTM/TB 2006. 362. Geneva, Switzerland: WHO; 2006
- Hesseling A, Schaaf H, Gie R, Starke J, Beyers N. A critical review of diagnostic approaches used in the diagnosis of childhood tuberculosis. Int J Tuberc Lung Dis 2002;6:1038- 45
- Starke J. Tuberculosis in children. Prim Care 1996;23:861-81 https://doi.org/10.1016/S0095-4543(05)70367-5
- Nelson LJ, Wells CD. Global epidemiology of childhood tuberculosis. Int J Tuberc Lung Dis 2004;8:636-47
- Corbett EL, Watt CJ, Walker N, Maher D, Williams BG, Raviglione MC, et al. The growing burden of tuberculosis: global trends and interactions with the HIV epidemic. Arch Intern Med 2003;163:1009-21 https://doi.org/10.1001/archinte.163.9.1009
- American Thoracic Society/Center for Disease Control and Prevention. Diagnostic standards and classification of tuberculosis in adults and children. Am J Respir Crit Care Med 2000;161:1376-95
- Kim SJ, Hong YP, Han YC, Kim SJ. Drug resistance of Mycobacterium tuberculosis in Korea. Tuberculosis Respir Dis 1991:38;99-107 https://doi.org/10.1016/0962-8479(92)90090-7
- Kwon KB, Park JY, Yoon BY, Kim MR, Lee HJ, Kim EJ, et al. The significance of bacteriologic examination in the childhood tuberculosis. J Korean Pediatr Soc 1994;37:221-9
- Bai GH, Park YK, Choi YW, Bai JI, Kim HJ, Chang CL, et al. Trend of anti-tuberculosis drug resistance in Korea, 1994-2004. Int J Tuberc Lung Dis 2007;11:571-6
- Pablos-Mendez A, Raviglione MC, Laszlo A, Binkin N, Rieder HL, Bustreo F, et al. Global surveillance for antituberculosis-drug resistance, 1994-1997. N Engl J Med 1998;338: 1641-9 https://doi.org/10.1056/NEJM199806043382301
- Nelson LJ, Schneider E, Wells CD, Moore M. Epidemiology of childhood tuberculosis in the united states, 19932001: The need for continued vgilance. Pediatrics 2004;114:333-41 https://doi.org/10.1542/peds.114.2.333
- Schaaf HS, Marias BJ, Hesseling AC, Gie RP, Beyers N, Donald PR. Childhood drug-resistant tuberculosis in the Western Cape Province of South Africa. Acta Paediatrica 2006;95:523-8 https://doi.org/10.1080/08035250600675741
- Ormerod LP. Rifampicin and isoniazid prophylactic chemotherapy for tuberculosis. Arch Dis Child 1998;78:169-71 https://doi.org/10.1136/adc.78.2.169
- Ena J, Valls V. Short-course therapy with rifampin plus isoniazid compared with standard therapy with isoniazid, for latent tuberculosis infection: a meta-analysis. Clin Infect Dis 2005;40:670-6 https://doi.org/10.1086/427802
- Mukherjee JS, Rich ML, Socci AR, Joseph JK, Viru FA, Shin SS, et al. Programmes and principles in treatment of multidrug-resistant tuberculosis. Lancet 2004;363:474-81 https://doi.org/10.1016/S0140-6736(04)15496-2
- Torun T, Gungor G, Ozmen I, Bolukbasi Y, Maden E, Bicakci B, et al. Side effects associated with the treatment of multidrug-resistant tuberculosis. Int J Tuberc Lung Dis 2005;9:1373-7
- Zignol M, Hosseini MS, Wright A, Weezenbeek CL, Nunn P, Watt CJ, et al. Global incidence of multidrug-resistant tuberculosis. J Infect Dis 2006;194:479-85 https://doi.org/10.1086/505877
- Aziz MA, Wright A, Laszlo A, De Muynck A, Portaels F, Van Deun A, et al. Epidemiology of anti-tuberculosis drug resistance (the global project on anti-tuberculosis drug resistance surveillance): an updated analysis. Lancet 2006;368: 2142-54 https://doi.org/10.1016/S0140-6736(06)69863-2
- World Health Organization. Anti-tuberculosis drug resistance in the world: 3rd Report: the WHO/IUATLD global project on anti-tuberculosis drug resistance surveillance 1999-2002 Geneva, Switzerland: WHO; 2004
- Dye C, Espinal MA, Watt CJ, Mbiaga C, Williams BG. Worldwide incidence of multidrug-resistant tuberculosis. J Infect Dis 2002;185:1197-202 https://doi.org/10.1086/339818
- Bai GH. Anti-tuberculosis drug resistance in Korea. CDMR 2005;16:101-7
- Park YK, Park YS, Bai JY, Kim HJ, Lew WJ, Chang CH, et al. Primary drug resistance rate of the private sector in 2003-2005. Tuberc Respir Dis 2008;64:87-94 https://doi.org/10.4046/trd.2008.64.2.87
- Korean Academy of Tuberculosis and Respiratory Diseases. Guideline for the management of pulmonary tuberculosis. Seoul: Korean Academy of Tuberculosis and Respiratory Diseases; 2005
- Schaaf HS, Gie RP, Kennedy M, Beyers N, Hesseling PB, Donald PR. Evaluation of young children in contact with adult multidrug-resistant pulmonary tuberculosis: a 30- month follow-up. Pediatrics 2002;109:765-71 https://doi.org/10.1542/peds.109.5.765
- World Health Organization. Global map and information on XDR-TB [internet]. Geneva, Switzerland: WHO; 2007 [cited 2007 Dec 31]. Available from: http://www.who.int/tb/challenges/xdr/xdrmap_oct07_en.pdf
- Raviglione MC, Smith IM. XDR tuberculosis implications for global public health. N Engl J Med 2007;356:656-9 https://doi.org/10.1056/NEJMp068273
- Centers for Disease Control and Prevention (CDC). Emergence of Mycobacterium tuberculosis with extensive resistance to second-line drug-worldwide, 2000-2004. MMWR Morb Mortal Wkly Rep 2006;55:301-5
- Choi JC, Lim SY, Suh GY, Chung MP, Kim HJ, Kwon OJ, et al. Drug resistance rates of Mycobacterium tuberculosis at a private referral center in Korea. J Korean Med Sci 2007;22:677-81 https://doi.org/10.3346/jkms.2007.22.4.677
- de Pontual L, Balu L, Ovetchkine P, Maury-Tisseron B, Lachassinne E, Cruaud P, et al. Tuberculosis in adolescents: A French retrospective study of 52 cases. Pediatr Infect Dis J 2006;25:930-2 https://doi.org/10.1097/01.inf.0000237919.53123.f4
피인용 문헌
- Clinical Characteristics of Tuberculosis in School-Age Children and Adolescents at a Single Institution vol.22, pp.3, 2012, https://doi.org/10.7581/pard.2012.22.3.239
- Anti-Tuberculosis Drug Resistant Rates inMycobacterium tuberculosisIsolated from Respiratory Specimens: A Multicenter Study in Korea vol.16, pp.1, 2009, https://doi.org/10.5145/acm.2013.16.1.1